Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2011

01-02-2011 | Melanomas

In Reply: Sentinel Lymph Node Biopsy in Melanoma

Authors: Ulrike Leiter, MD, Claus Garbe, MD

Published in: Annals of Surgical Oncology | Issue 2/2011

Login to get access

Excerpt

Di Georgi and colleagues propose that sentinel lymph node biopsy (SLNB) does not provide a real survival benefit and that the disease-free survival benefit is a result of lead-time bias. These are old arguments that have been repeatedly discussed in the literature.1‐7 A reiterative statement of these arguments does not make them truer. The only new idea in the letter of Di Georgi and colleagues is to designate the gain of disease-free survival time as lead-time bias that shows that they did not really understand the concept of lead time bias.8‐11 …
Literature
1.
Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151:298–307.CrossRefPubMed
2.
Medalie NS, Ackerman AB. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part II. Am J Dermatopathol. 2003;25:473–84.CrossRefPubMed
3.
Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151:308–19.CrossRefPubMed
4.
Thomas JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma. BMJ. 2000;321:3–4.CrossRefPubMed
5.
Thomas JM, Clark MA. Sentinel lymph node biopsy: not yet standard of care for melanoma. BMJ. 2004;329:170–1.CrossRefPubMed
6.
Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol. 2001;14:604–8.CrossRefPubMed
7.
Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6:659–70.CrossRefPubMed
8.
Black WC. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst. 2000;92:1280–2.CrossRefPubMed
9.
Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol. 2008;168:98–104.CrossRefPubMed
10.
Jacques PF, Hartz SC, Tuthill RW, Hollingsworth C. Elimination of “lead time” bias in assessing the effect of early breast cancer diagnosis. Am J Epidemiol. 1981;113:93–7.PubMed
11.
Kafadar K, Prorok PC. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials. Stat Med. 1994;13:569–86.CrossRefPubMed
12.
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.CrossRefPubMed
13.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMed
14.
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.CrossRefPubMed
Metadata
Title
In Reply: Sentinel Lymph Node Biopsy in Melanoma
Authors
Ulrike Leiter, MD
Claus Garbe, MD
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1068-2

Other articles of this Issue 2/2011

Annals of Surgical Oncology 2/2011 Go to the issue

Neuro-Oncology

Predictors of Inpatient Death and Complications among Postoperative Elderly Patients with Metastatic Brain Tumors

Endocrine Tumors

Robotic-Assisted Resection of Adrenal Aldosteronoma

Thoracic Oncology

Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy

Healthcare Policy and Outcomes

Extent of Gastric Resection Impacts Patient Quality of Life: The Dysfunction after Upper Gastrointestinal Surgery for Cancer (DAUGS32) Scoring System

Pancreatic Tumors

Laparoscopic Pancreatectomy for Solid Pseudo-Papillary Tumors of the Pancreas is a Suitable Technique; Our Experience with Long-Term Follow-up and Review of the Literature

Endocrine Tumors

Reply to “25-Hydroxyvitamin D Status Does Not Affect Intraoperative Parathyroid Hormone Dynamics in Patients With Primary Hyperparathyroidism,” by Agarwal et al.